Nabeel Bardeesy
Overview
Explore the profile of Nabeel Bardeesy including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
206
Citations
22962
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Park J, Mortaja M, Son H, Zhao X, Sloat L, Azin M, et al.
Nat Commun
. 2024 May;
15(1):4099.
PMID: 38816352
Chronic inflammation is a major cause of cancer worldwide. Interleukin 33 (IL-33) is a critical initiator of cancer-prone chronic inflammation; however, its induction mechanism by environmental causes of chronic inflammation...
12.
13.
Zhen Y, Liu K, Shi L, Shah S, Xu Q, Ellis H, et al.
Nat Commun
. 2024 May;
15(1):3805.
PMID: 38714664
Genomic alterations that activate Fibroblast Growth Factor Receptor 2 (FGFR2) are common in intrahepatic cholangiocarcinoma (ICC) and confer sensitivity to FGFR inhibition. However, the depth and duration of response is...
14.
Balasooriya E, Wu Q, Ellis H, Zhen Y, Norden B, Corcoran R, et al.
Clin Cancer Res
. 2024 Mar;
30(10):2181-2192.
PMID: 38437671
Purpose: FGFR2 and FGFR3 show oncogenic activation in many cancer types, often through chromosomal fusion or extracellular domain mutation. FGFR2 and FGFR3 alterations are most prevalent in intrahepatic cholangiocarcinoma (ICC)...
15.
Cattaneo G, Ventin M, Arya S, Kontos F, Michelakos T, Sekigami Y, et al.
Cancer Lett
. 2024 Feb;
587:216713.
PMID: 38364961
Human leukocyte antigen (HLA) class I defects are associated with cancer progression. However, their prognostic significance is controversial and may be modulated by immune checkpoints. Here, we investigated whether the...
16.
Chen J, Amoozgar Z, Liu X, Aoki S, Liu Z, Shin S, et al.
Cancer Immunol Res
. 2024 Jan;
12(4):400-412.
PMID: 38260999
Intrahepatic cholangiocarcinoma (ICC) has limited therapeutic options and a dismal prognosis. Adding blockade of the anti-programmed cell death protein (PD)-1 pathway to gemcitabine/cisplatin chemotherapy has recently shown efficacy in biliary...
17.
Ben-Ami R, Wang Q, Zhang J, Supplee J, Fahrmann J, Lehmann-Werman R, et al.
Gut
. 2023 Dec;
73(4):639-648.
PMID: 38123998
Objective: Pancreatic ductal adenocarcinoma (PDAC) is commonly diagnosed at an advanced stage. Liquid biopsy approaches may facilitate detection of early stage PDAC when curative treatments can be employed. Design: To...
18.
Takahashi M, Chong H, Zhang S, Lazarov M, Harry S, Maynard M, et al.
bioRxiv
. 2023 Nov;
PMID: 37961514
Cysteine-focused chemical proteomic platforms have accelerated the clinical development of covalent inhibitors of a wide-range of targets in cancer. However, how different oncogenic contexts influence cysteine targeting remains unknown. To...
19.
Wu Q, Ellis H, Siravegna G, Michel A, Norden B, Fece de la Cruz F, et al.
Clin Cancer Res
. 2023 Oct;
30(1):198-208.
PMID: 37843855
Purpose: FGFR inhibitors are effective in FGFR2-altered cholangiocarcinoma, leading to approval of reversible FGFR inhibitors, pemigatinib and infigratinib, and an irreversible inhibitor, futibatinib. However, acquired resistance develops, limiting clinical benefit....
20.
Kato H, Ellis H, Bardeesy N
Clin Cancer Res
. 2023 Sep;
29(22):4527-4529.
PMID: 37695631
In a landscape dominated by pivotal KRAS mutations, there has been limited exploration of KRAS wild-type pancreatic cancer. A recent study highlights other mitogen-activated kinase pathway alterations as alternative drivers...